ClinicalTrials.gg

Program

Risperidone

Also written as “risperidone”, “Oral risperidone” and “Risperidone ISM 100 mg”.

Its studies are mostly in Schizophrenia · Bipolar Disorder · Psychotic Disorders · Autistic Disorder · Dementia, led by 15 companies.

Furthest: phase 4, since Jun 4, 200399 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson670 open or runningphase 4since Jun 4, 2003May 2, 2002none ahead
Rovi Pharmaceuticals Laboratories50 open or runningphase 3since May 12, 2017Feb 5, 2013none ahead
Teva Pharmaceutical Industries40 open or runningphase 3since Apr 9, 2018Jan 26, 2009none ahead
AstraZeneca30 open or runningphase 4since Nov 14, 2005May 2, 2002none ahead
Luye Pharma Group30 open or runningphase 1since Jan 31, 2014Jan 31, 2014none ahead
Lyndra30 open or runningphase 3since Mar 9, 2023Sep 16, 2020none ahead
Braeburn Pharmaceuticals20 open or runningphase 3since May 11, 2016Jan 7, 2016none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since Feb 4, 2010Feb 4, 2010none ahead
IPCA Laboratories20 open or runningphase 1since Jun 11, 2012Jun 11, 2012none ahead
Sun Pharmaceutical Industries20 open or runningno phasesince Oct 15, 2010Oct 15, 2010none ahead
Torrent Pharmaceuticals20 open or runningphase 1since Jul 10, 2009Jul 10, 2009none ahead
delpor-inc10 open or runningphase 2since Jun 1, 2020Jun 1, 2020none ahead
Indivior Pharmaceuticals10 open or runningphase 4since May 30, 2019May 30, 2019none ahead
Pfizer10 open or runningno phasesince Sep 9, 2005Sep 9, 2005none ahead
yung-shin-pharm-ind-co-ltd10 open or runningphase 2since Oct 23, 2023Oct 23, 2023none ahead

Also a collaborator on its studies: Otsuka and H. Lundbeck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Nov 10, 2005.

  1. Jul 14, 2017Phase 1 study in HealthyJohnson & Johnson · NCT03220867 · China
  2. Apr 9, 2018Phase 3 study in SchizophreniaTeva Pharmaceutical Industries · NCT03503318 · 544 enrolled · United States, Bulgaria
  3. May 4, 2018Phase 1 study in SchizophreniaRovi Pharmaceuticals Laboratories · NCT03527186 · 81 enrolled · United States
  4. Oct 18, 2018Phase 4 study in SchizophreniaJohnson & Johnson · NCT03713658 · 34 enrolled · Rwanda
  5. Feb 26, 2019Phase 3 study in SchizophreniaRovi Pharmaceuticals Laboratories · NCT03870880 · 215 enrolled · United States, Ukraine
  6. Mar 27, 2019Phase 3 study in SchizophreniaTeva Pharmaceutical Industries · NCT03893825 · 336 enrolled · United States, Bulgaria, Canada and more
  7. May 30, 2019Indivior Pharmaceuticals's first study: phase 4 study in SchizophreniaNew to Indivior PharmaceuticalsIndivior Pharmaceuticals · NCT03978832 · 69 enrolled · United States
  8. Jun 1, 2020delpor-inc's first study: phase 2 study in SchizophreniaNew to delpor-incdelpor-inc · NCT04418466 · 34 enrolled · United States
  9. Sep 16, 2020Lyndra's first study: phase 2 study in Psychotic DisordersNew to LyndraLyndra · NCT04567524 · 34 enrolled · United States
  10. Jun 22, 2021Phase 4 study in SchizophreniaJohnson & Johnson · NCT04940039 · 93 enrolled · Rwanda
  11. Dec 16, 2021Phase 1 study in SchizophreniaRovi Pharmaceuticals Laboratories · NCT05179525 · 80 enrolled · United States
  12. Mar 9, 2023Phase 3 study in SchizophreniaLyndra · NCT05779241 · 83 enrolled · United States
  13. Oct 23, 2023yung-shin-pharm-ind-co-ltd's first study: phase 2 study in Hot FlashesNew to yung-shin-pharm-ind-co-ltdyung-shin-pharm-ind-co-ltd · NCT06161792 · 10 enrolled · Taiwan
  14. Feb 25, 2025Phase 3 study in SchizophreniaLyndra · NCT06878833

TargetBeta

“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
OlanzapineruleEli Lillyphase 476

Studies

The newest 60 of 99 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06878833Schizophrenia3WithdrawnLyndraDec 31, 20260
NCT06161792Hot Flashes · Taiwan2Terminatedyung-shin-pharm-ind-co-ltdMar 14, 202210
NCT05779241Schizophrenia · United States3CompletedLyndraNov 3, 202383
NCT05179525Schizophrenia · United States1CompletedRovi Pharmaceuticals LaboratoriesSep 17, 202180
NCT04940039Schizophrenia · Rwanda4CompletedJohnson & JohnsonApr 16, 202493
NCT04567524Psychotic Disorders · United States2CompletedLyndraDec 22, 202034
NCT04418466Schizophrenia · United States2Completeddelpor-incFeb 10, 202334
NCT03978832Schizophrenia · United States4CompletedIndivior PharmaceuticalsMay 12, 202069
NCT03893825Schizophrenia · United States, Bulgaria, Canada and more3CompletedTeva Pharmaceutical IndustriesDec 2, 2021336
NCT03870880Schizophrenia · United States, Ukraine3CompletedRovi Pharmaceuticals LaboratoriesJan 8, 2020215
NCT03713658Schizophrenia · Rwanda4CompletedJohnson & JohnsonDec 2, 201934
NCT03527186Schizophrenia · United States1CompletedRovi Pharmaceuticals LaboratoriesMar 23, 201981
NCT03503318Schizophrenia · United States, Bulgaria3CompletedTeva Pharmaceutical IndustriesSep 30, 2020544
NCT03220867Healthy · China1WithdrawnJohnson & JohnsonJan 2, 20180
NCT03160521Acute Schizophrenia · United States, Ukraine3CompletedRovi Pharmaceuticals LaboratoriesDec 17, 2018438
NCT02773576Schizophrenia · United States3CompletedBraeburn PharmaceuticalsSep 2017140
NCT02658357Schizophrenia · United States2CompletedBraeburn PharmaceuticalsAug 201766
NCT02634463Immunoassay · Belgium1CompletedJohnson & JohnsonNov 9, 201681
NCT02462473Schizophrenia · United States2TerminatedJohnson & JohnsonJan 20169
NCT02186769Schizophrenia · United States1CompletedLuye Pharma GroupApr 201516
NCT02091388Schizophrenia · United States1CompletedLuye Pharma GroupJan 2015108
NCT02087579Psychotic Disorders · United States, Argentina, Belgium and more1CompletedJohnson & JohnsonOct 2014305
NCT02055287Schizophrenia · United States1CompletedLuye Pharma GroupJun 201436
NCT01855074Schizophrenia4CompletedJohnson & JohnsonFeb 200980
NCT01788774Schizophrenia · Croatia, Russian Federation, South Africa and more1CompletedRovi Pharmaceuticals LaboratoriesFeb 201436
NCT01726335Schizophrenia · Brazil4CompletedJohnson & JohnsonMar 200853
NCT01722201Fasting · India1CompletedIPCA LaboratoriesSep 201248
NCT01624675Autistic Disorder · Japan3CompletedJohnson & JohnsonOct 201439
NCT01618760Lecithin Cholesterol Acyltransferase Deficiency · India1CompletedIPCA LaboratoriesJun 201248
NCT01607762Healthy · Belgium1CompletedJohnson & JohnsonApr 201231
NCT01222975Healthy · United States–CompletedSun Pharmaceutical IndustriesOct 200444
NCT01222923Healthy · United States–CompletedSun Pharmaceutical IndustriesOct 200440
NCT01064271Healthy1CompletedDr. Reddy's LaboratoriesOct 200626
NCT01064232Healthy1CompletedDr. Reddy's LaboratoriesOct 200630
NCT01050582Schizophrenia · United States, Belgium, Germany and more4CompletedJohnson & JohnsonJul 2011244
NCT00992407Schizophrenia · Korea, Republic of4CompletedJohnson & JohnsonDec 201075
NCT00986336Bipolar Disorder1CompletedJohnson & Johnson56
NCT00939926Healthy · India1CompletedTorrent Pharmaceuticals
NCT00939497Healthy · India1CompletedTorrent Pharmaceuticals
NCT00934635Schizophrenia · Germany4TerminatedJohnson & JohnsonDec 20092
NCT00830349Healthy · Canada1CompletedTeva Pharmaceutical IndustriesJul 200130
NCT00829894Healthy · Canada1CompletedTeva Pharmaceutical IndustriesJul 200124
NCT00645502Schizophrenia1CompletedJohnson & Johnson40
NCT00576732Autistic Disorder · United States4CompletedJohnson & JohnsonSep 200996
NCT00558298Schizophrenia3CompletedJohnson & Johnson811
NCT00535132Schizophrenia · United States, Argentina, Colombia and more4CompletedJohnson & JohnsonJul 2008201
NCT00526877Schizophrenia · Taiwan4CompletedJohnson & JohnsonJan 31, 200931
NCT00495118Schizophrenia3CompletedJohnson & Johnson314
NCT00378183Psychotic Disorders4CompletedJohnson & Johnson120
NCT00378092Schizophrenia · South Africa4CompletedJohnson & JohnsonMar 201033
NCT00305422Schizophrenia · Germany3CompletedAstraZeneca45
NCT00287742Alzheimer Disease3TerminatedJohnson & Johnson33
NCT00266552Conduct Disorder3CompletedJohnson & Johnson118
NCT00261508Autistic Disorder3CompletedJohnson & Johnson80
NCT00257075Bipolar Disorder3CompletedJohnson & Johnson267
NCT00254930Learning Disabilities3CompletedJohnson & Johnson19
NCT00254241Schizophrenia · United Kingdom4CompletedAstraZeneca80
NCT00253162Bipolar Disorder3CompletedJohnson & Johnson439
NCT00253149Bipolar Disorder3CompletedJohnson & Johnson158
NCT00253136Schizophrenia3CompletedJohnson & Johnson458

How it is read

Names in the registry

  • “risperidone”, 40 entries
  • “Risperidone”, 34 entries
  • “Oral risperidone”, 5 entries
  • “Risperidone ISM 100 mg”, 3 entries
  • “LY03004”, 3 entries

Codes read as this program: LYN005.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.